Propeller Health has announced that its inhaler monitoring platform has received 510(k) clearance from the FDA for use with the Ellipta dry powder inhaler. The company had announced a deal with GSK to develop a sensor for the Ellipta DPI in December 2015.
GSK Head of Respiratory R&D Dave Allen commented, “While it is still in the early stages of development, the emerging field of digital healthcare holds great promise for respiratory medicine. The approval of the Propeller platform for use with the Ellipta inhaler will help us understand how patients interact with the Ellipta inhaler accurately and in real-time. By exploring the benefits of sensor technology in this way, we hope to gain valuable insights into usage patterns with the ultimate goal of driving improvements in patient care while reducing the complexity and cost of clinical trials.”
Propeller Co-Founder and CEO David Van Sickle said, “Inclusion of GSK’s Ellipta inhaler in Propeller’s digitally-guided therapy platform is an important step in our goal of modernizing the management of respiratory disease. We look forward to working closely with GSK to deploy sensors for the Ellipta inhaler in the US and abroad, in the near term.”
Read the Propeller Health press release.
